Vast Therapeutics is a preclinical stage biotechnology company developing inhalable therapeutics to treat chronic infections common to the cystic fibrosis population. |
About UsVast Therapeutics is a development-stage pharmaceutical company that develops therapies to treat resistant bacteria and enable patients suffering from severe respiratory diseases to breathe better and live life more fully.
|
TechnologyVast Therapeutics’ solutions will provide cystic fibrosis patients with a convenient and effective inhalable treatment for drug-resistant respiratory infections.
|
InvestorsWe are committed to bring breakthrough antimicrobial therapies to market that address the growing needs of patients with severe lung diseases like cystic fibrosis.
|
RECENT NEWS
|
Vast Therapeutics Announces BIOC11 testing results for Nontuberculous Mycobacteria (NTM) in Animal Model
Oct 22, 2019 DURHAM, N.C., Oct. 22, 2019 -- Vast Therapeutics, Inc., a subsidiary of KNOW Bio, LLC, announces that BIOC11 eradicated 99% of the Nontuberculous Mycobacteria (NTM) in an in vivo animal model of infection; this data will be presented at the National Cystic Fibrosis Conference to be held in Nashville, Tennessee from October 31 to November 2, 2019. |
Vast Therapeutics Receives Qualified Infectious Disease Product Status for BIOC11
Oct 8, 2019 DURHAM, NC – October 8, 2019 – Vast Therapeutics, Inc., a subsidiary of KNOW Bio, LLC, today announced that another of its drug candidates, BIOC11, has been designated as a “Qualified Infectious Disease Product” (QIDP) by the U.S. Food and Drug Administration. |
KNOW Bio Announces Closing of $30 Million in Equity Financing
May 15, 2019 DURHAM, N.C., May 15, 2019 /PRNewswire/ -- KNOW Bio, LLC, (the Company or KNOW Bio), an RTP based conglomerate of biotechnology and MedTech companies, announced today that the Company has completed its next round of financing with a single investor, Reedy Creek Investments, LLC (Reedy Creek). |
